|Bid||0.0900 x 0|
|Ask||0.1000 x 0|
|Day's Range||0.0950 - 0.1050|
|52 Week Range||0.0650 - 0.1800|
|Beta (5Y Monthly)||0.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 30, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.52|
/NOT FOR DISTRIBUTION TO U. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/VANCOUVER, BC, Aug.
/NOT FOR DISTRIBUTION TO U. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/VANCOUVER, BC, July 28, 2020 /CNW/ - Aequus Pharmaceuticals Inc.
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today a grant of 1,124,337 stock options to the Chief Operating Officer to replace the same number of previously issued options that expired on May 31, 2020. The terms of the stock options granted on June 4, 2020 are in accordance with the Company’s Stock Option Plan.